Ontozry

News

Angelini rapped for criticism of EMA approval

Angelini has been rapped under the UK pharma industry's code of practice for criticising licensing decisions made by the EMA and other breaches.

News

Illustration of a nerve cell on a colored background with light effects

Drug-resistant epilepsy drug Ontozry backed by NICE

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharm

News

Vogenx surpasses expectations with $81M IPO

With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks